Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Single-Arm Feasibility Study to Determine the Capacity of the Onco-Seraph 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) to Remove Circulating Tumor Cells From the Blood of Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06481397 is registered in ClinicalTrials.gov with ExThera Medical Corporation as lead sponsor.

NCT NCT06481397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06481397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Single-Arm Feasibility Study to Determine the Capacity of the Onco-Seraph 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) to Remove Circulating Tumor Cells From the Blood of Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Lead sponsor
ExThera Medical Corporation
Phase
Not applicable
Overall status
Completed
Start date
August 29, 2024
Completion date
October 18, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac)